Thrombin Generation Decrease After LMWH Administration in an Antithrombin-Deficient Pregnant Woman With a Homozygous HBS II Mutation
Clinical and Applied Thrombosis/Hemostasis · 2023
DOI: 10.1177/10760296231197174 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Ivana Malikova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Central Hematological Laboratory, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Antithrombin III Deficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Czech Republic – conceptual development of research organization 64165, General University Hospital in Prague, Czech Republic.
Abstract (Originalsprache)
The cases of antithrombin (AT)-deficient pregnant women with a homozygous HBS II mutation are relatively rare and are accompanied by an increased thrombophilic risk, which is manifested by increased thrombin generation (TG). It is very difficult to ensure their prophylactic treatment during pregnancy. We aimed to determine the utility of the thrombin generation assay (TGA) and anti-factor Xa (anti-FXa) test to monitor the effects of a prophylactic dose of low-molecular-weight heparin (LMWH) in a 28-year-old woman with homozygous AT deficiency caused by mutation c.391C > T#, (p.Leu131Phe†) in the SERPINC1 gene and to compare the findings with those from a group of pregnant and non-pregnant women also treated with LMWH. TG monitoring was chosen due to severe AT deficiency that was manifested by low levels of anti-FXa activity when monitoring the efficacy of LMWH treatment. A significant decrease in TG was detected in all monitored groups ( P < .05). There were no thrombotic complications during the whole pregnancy of the woman with AT deficiency. Consistent monitoring of TG with LMWH anticoagulant therapy administration during pregnancy together with AT administration before and after delivery may improve the overall condition of pregnant women and the quality of their care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Hematological Laboratory, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
- Thrombotic Centre of Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
ORCID-Profile: Ivana Malikova
Förderung
- Ministry of Health, Czech Republic – conceptual development of research organization 64165, General University Hospital in Prague, Czech Republic
Zitieren
APA
Malikova, I., Husakova, M., Bilkova, J., Brzezkova, R., Hrachovinova, I., & Kvasnicka, T. (2023). Thrombin Generation Decrease After LMWH Administration in an Antithrombin-Deficient Pregnant Woman With a Homozygous HBS II Mutation. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296231197174
Vancouver
Malikova I, Husakova M, Bilkova J, Brzezkova R, Hrachovinova I, Kvasnicka T. Thrombin Generation Decrease After LMWH Administration in an Antithrombin-Deficient Pregnant Woman With a Homozygous HBS II Mutation. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296231197174
BibTeX
@article{Malikova2023,
author = {Malikova, Ivana and Husakova, Martina and Bilkova, Jana and Brzezkova, Radka and Hrachovinova, Ingrid and Kvasnicka, Tomas},
title = {Thrombin Generation Decrease After LMWH Administration in an Antithrombin-Deficient Pregnant Woman With a Homozygous HBS II Mutation},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2023},
doi = {10.1177/10760296231197174}
}
EUVIMED